Clinical Trial Update: Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial of intrathecal rituximab for lymphoid malignancies involving the central nervous system was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Leukemia
• Lymphoid Malignancies

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Lymphoid Malignancies | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-03-27